Udayavni Special

Biophore applies to DCGI for emergency-use approval for COVID-19 treatment drug


PTI, Jun 11, 2021, 2:39 PM IST

New Delhi: Biophore India Pharmaceuticals on Friday said it has applied to the Drugs Controller General of India (DCGI) for obtaining emergency-use approval for Aviptadil, used in the treatment of moderate to severe cases of COVID-19.

The Hyderabad-based firm said it has developed the product which is backwards integrated with its in-house API (Active Pharmaceutical Ingredient).

The company plans to commence commercial production of the product immediately after the approval is received, it added.

Aviptadil is a synthetic form of Vasoactive Intestinal Peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection.

These observations are based on results of multiple trials of Aviptadil against COVID-19 globally in patients with respiratory failure and the same has been submitted to DCGI for their review.

“The company has developed this highly complex peptide in a very short period of time, primarily due to the extensive focus of the company in prioritising COVID related products over the last one year,” Biophore CEO Jagadeesh Babu Rangisetty said in a statement.

Aviptadil is a very promising treatment option for COVID, especially in severe hospitalised cases where trials have shown a high recovery percentage, he added.

“We hope to be able to quickly make it available through this approval,” Rangisetty noted.

Biophore was one of the first few manufacturers to have received approval for an antiviral agent, Favipiravir, in the country during the first wave of COVID-19 and is also the only Indian manufacturer to be producing multi tonnage volumes of Sulfobutyl Ether beta Cyclodextrin (SBECD), which is a key excipient in the manufacturing of Remdesivir Injections.

Apart from these, the company said it has invested significantly into the research and development of other anti-COVID products over the last one year.

“While we are optimistic that the pandemic will end soon, we have to be prepared for the exigencies. We need to keep evaluating and adding newer products against this virus to ensure better preparedness by having more options for the treating physicians and thus avoiding shortages. Our aim is also to make the cost of treatment affordable, especially for hospitalised patients,” Rangisetty said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

State reports 5,783 new Covid-19 cases, 168 deaths; DK crosses 1000 Covid mark again

Mangaluru: Man arrested for insulting Tulunadu flag

Joe Biden gifts Vladimir Putin pair of iconic American-made aviators

Police investigating MLA’s allegation of phone tapping & conspiracy to fix him: Min Bommai

No political crisis at all in Karnataka, says CM Yediyurappa

Bharat Biotech’s pre-submission meeting for Covaxin EUL with WHO on June 23

‘Baba Ka Dhaba’ owner Kanta Prasad hospitalised after suicide attempt



Related Articles More

Pfizer, Moderna COVID-19 vaccines don’t lower sperm count, study says

PM Modi launches crash course to skill, upskill over 1 lakh ‘Covid warriors’

A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits

We archived 84 million tweets to learn about the pandemic – each one is a tiny historical document

Delta variant infections doubling every 11 days in England, study finds

MUST WATCH

Impact of COVID-19 on public transport

Udayavani 18-JUN-2021 News Bulletin

Scenic views of Jog Falls

ಯಾರೋ ಒಬ್ಬಿಬ್ಬರು ಮಾತನಾಡಿದರೆ ಗೊಂದಲವಾಗುವುದಿಲ್ಲ CM B S Yediyurappa

Weekend Curfew Rules and Regulations in Udupi

Latest Additions

State reports 5,783 new Covid-19 cases, 168 deaths; DK crosses 1000 Covid mark again

Mangaluru: Man arrested for insulting Tulunadu flag

Bengaluru likely to receive rain in next 24 hours: IMD

Karnataka govt dismisses BJP MLC’s Rs 21,473 cr tender scam allegation

Hyundai drives in new SUV Alcazar at Rs 16.3 lakh

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.